POEMS syndrome synonyms

TL;DR: POEMS syndrome is a rare multisystem disorder primarily known by its acronym, which stands for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes. While it is occasionally referred to as Crow-Fukase syndrome, Takatsuki syndrome, or PEP syndrome in historical or international literature, POEMS syndrome remains the universally accepted clinical term used by medical professionals today.

What are the historical and alternative names for POEMS syndrome?

Because POEMS syndrome involves a complex interplay of neurological, endocrine, and hematological systems, it has been described using several different names throughout its history. In older medical literature, particularly in Japan, you may encounter the term Crow-Fukase syndrome, named after the physicians who first characterized the clinical presentation. Other historical designations include Takatsuki syndrome and PEP syndrome (referring to polyneuropathy, endocrinopathy, and plasma cell dyscrasia). These names are largely obsolete, though they persist in archival research papers and certain regional medical traditions.

Why does POEMS syndrome have multiple names?

The variety of names for POEMS syndrome stems from the medical community's evolving understanding of the disease over several decades. Initially, clinicians identified isolated features, such as polyneuropathy or skin pigment changes, and named the condition after their own observations. As the underlying pathophysiology—specifically the presence of a monoclonal plasma cell disorder—became better understood, the acronym "POEMS" was adopted to provide a concise, descriptive summary of the five core diagnostic criteria. Today, the medical community favors the acronym POEMS syndrome because it acts as a clinical mnemonic, helping physicians remember the essential features required for a diagnosis.

How is POEMS syndrome classified in medical systems?

For the purposes of clinical documentation, insurance coding, and research, POEMS syndrome is categorized under standardized medical systems. These classifications ensure that patients and researchers are referring to the same clinical entity across global databases:

• Orphanet: Listed as ORPHA:2906, categorized under rare plasma cell dyscrasias.


• OMIM (Online Mendelian Inheritance in Man): Referenced under ID #603496.


• ICD-10/11: Often coded under related plasma cell dyscrasias or polyneuropathy codes, as it is a rare systemic condition.


• NIH GARD: Recognized as a distinct multisystem disorder under the specific name POEMS syndrome.

What are the core components of the POEMS syndrome acronym?

Understanding the name of POEMS syndrome is essential for navigating your medical records. The acronym represents the mandatory and secondary features that define the condition:

• P: Polyneuropathy (typically a progressive, symmetric, distal sensorimotor neuropathy).


• O: Organomegaly (often involving the liver, spleen, or lymph nodes).


• E: Endocrinopathy (hormonal imbalances affecting the thyroid, adrenal, or gonadal glands).


• M: Monoclonal plasma cell disorder (a key diagnostic marker found in the blood).


• S: Skin changes (such as hyperpigmentation, hypertrichosis, or hemangiomas).

At DiseaseMaps.org, 59 people with POEMS syndrome have joined our community to share their experiences and help others navigate these complex diagnostic terms. Utilizing the standard name "POEMS syndrome" when speaking with your care team ensures clear communication and aligns your treatment plan with current international clinical guidelines.

Next steps

• Consult with a hematologist-oncologist or a neurologist who specializes in plasma cell dyscrasias.


• Request a copy of your diagnostic reports and ensure they reflect the current terminology for POEMS syndrome for insurance and referral purposes.


• Join our community at DiseaseMaps.org to connect with 59 other members who can provide peer support and shared knowledge about living with this condition.


• Review the latest clinical trial information via the NIH GARD portal to stay updated on emerging therapeutic options.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with a qualified healthcare provider regarding your specific medical condition.

References

• Orphanet: POEMS Syndrome (ORPHA:2906)


• NIH Genetic and Rare Diseases Information Center (GARD): POEMS Syndrome


• OMIM: POEMS Syndrome (#603496)


• Dispenzieri, A. (2019). POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. American Journal of Hematology.